A survey of 24 international heart valve banks was conducted to acquire information on heart valve processing techniques used and outcomes achieved. The objective was to provide an overview of heart valve banking activities for tissue bankers, tissue banking associations, and regulatory bodies worldwide. Despite similarities found for basic manufacturing processes, distinct differences in procedural details were also identified. The similarities included (1) use of sterile culture media for procedures, (2) antibiotic decontamination, (3) use of dimethyl sulfoxide (DMSO) as a cryoprotectant, (4) controlled rate freezing for cryopreservation, and (5) storage at ultralow temperatures of below −135 ∘ C. Differences in procedures included (1) type of sterile media used, (2) antibiotics combination, (3) temperature and duration used for bioburden reduction, (4) concentration of DMSO used for cryopreservation, and (5) storage duration for released allografts. For most banks, the primary reasons why allografts failed to meet release criteria were positive microbiological culture and abnormal morphology. On average, 85% of allografts meeting release criteria were implanted, with valve size and type being the main reasons why released allografts were not used clinically. The wide variation in percentage of allografts meeting release requirements, despite undergoing validated manufacturing procedures, justifies the need for regular review of important outcomes as cited in this paper, in order to encourage comparison and improvements in the HVBs' processes.
Introduction
Since the first heart valve bank (HVB) started in New Zealand in 1962, the recovery, processing, and storage techniques have been constantly evolving to improve the quality and safety of cardiovascular allografts for clinical implantation. During the initial era of allograft usage, fresh aseptically recovered allografts were implanted within hours or days of recovery. This was followed by aggressive decontamination methods, such as gamma-irradiation and chemical sterilisation using formaldehyde, glutaraldehyde, beta-propiolactone, and ethylene oxide. Coupled with harsh preservation techniques of freeze-drying and flash-freezing in liquid nitrogen, these "sterilised" tissues rapidly failed in situ due to high incidence of leaflet degeneration, cusp rupture, and/or loss of durability and hemodynamic function. For these reasons, allograft use was discontinued until newer preservation methods were developed. Eventually, "sterilised" tissues were replaced by aseptically recovered ones treated with antibiotics and stored in culture media at 4 ∘ C for up to 6 weeks. These milder techniques improved valve durability and, ultimately, patient outcome. Today, the majority of HVBs worldwide use aseptic retrieval of donor heart valves followed by low-dose antibiotic decontamination, cryopreservation, and storage at ultralow temperature until the valves are required for implantation [1] [2] [3] .
Regulatory bodies throughout the world promote global harmonisation of manufacturing procedures as a mean to standardise product quality and safety and to simplify the exchange of "like" products between jurisdictions. Although 2 Journal of Transplantation standardisation is a rational approach for many processes, genuine differences and restrictions in manufacturing circumstances, such as differences in endemic microbial contaminants and patented processes, may limit the extent to which standardisation can be achieved. In addition, as changes to critical processes require validation, which can be both costly and time consuming, any proposed change must be justified in terms of risks and cost benefits for the HVB and the recipient. As a result, even though tissue banking associations and regulatory bodies governing HVBs worldwide promote similar quality and safety standards for allografts, differences in processing procedures used to achieve these outcomes continue to exist. Essentially, all HVBs follow standards developed by their regional tissue banking associations, which are designed to meet regulatory requirements of their jurisdiction. In all cases, the standards developed by these tissue-banking associations stipulate donor suitability criteria, aseptic processing procedures, and controlled storage requirements of transplantable human tissues, with the common objective of assuring that recipients receive disease-and contaminantfree allografts that fulfil optimum clinical performance [2] . In February 2011, a survey of 24 HVBs in North America, Europe, Australasia, and South Africa was initiated by coauthor Linda Manning. The survey was designed to collate data on heart valve processing procedures and outcomes to inform HVBs and their regulatory bodies on the similarities and differences in heart valve manufacturing activities worldwide. This information was subsequently compiled and presented at the ATBF's 12th Annual Scientific and Business meeting held in Melbourne, Australia, in May 2011 and the AATB's 
Materials and Methods
The original survey was distributed by electronic mail to 24 HVBs in North America, Europe, Australia, New Zealand, Asia, and South Africa. They were asked to provide information to the following questions, which addressed two aspects. Data was collated from February to April 2011. In this report, the results were summarised and presented as returned, apart for editing for consistency of terminology.
The individual HVBs had been deidentified. The Royal Perth Hospital's Cell and Tissue Therapies WA's Management Committee was consulted prior to implementation of study, and ethics approval was advised to be unnecessary, as the survey was a mere collation of information on the individual HVBs' practices and outcomes, which did not involve the identification of patients.
Results

Tissue Processing and Storage
Procedures. 24 HVBs participated in this aspect of study. As presented in Tables 1, 2 , and 3, both similarities and differences in heart valve processing and storage procedures were identified in the survey. Isotonic solutions or cell culture media were used for valve retrieval, antibiotic decontamination, and cryopreservation. Eleven HVBs (46%) used Medium 199 (M199), and five (21%) used Roswell Park Memorial Institute Media 1640 (RPMI-1640), while the remainder used Dulbecco's Modified Eagle's Medium (DMEM), sodium chloride (normal saline), Hanks Balanced Salt Solution (HBSS), or Ringer's lactate (Table 5) . Twelve of the 18 HVBs (66%) reported using 9%-11% DMSO as cryoprotectant, with the rest using varying concentrations of DMSO (7.5%-20%) with or without foetal bovine serum or human albumin. In all cases, the media/solutions were purchased as sterile reagents from approved suppliers.
Antibiotic decontamination regimens were found to be exceptionally diverse, both in the antibiotic combinations used (Tables 1-3 ) and their concentrations ( Table 4) . The most commonly used antibiotics were vancomycin (15 banks) and gentamicin (10 banks). Seven HVBs also included antifungal drugs in their antibiotic cocktail-five used amphotericin B, one used fluconazole, and another used fungoral.
Most of the European HVBs and half of the North American HVBs surveyed incubated allografts at 4 ∘ C for 24 hours. In contrast, five of the seven HVBs surveyed from Australasia and South Africa decontaminated their valves at physiological temperature of 37 ∘ C for ≤12 hours. Overall, 16 HVBs (67%) conducted bioburden reduction at cold temperatures (1 ∘ C-10 ∘ C), with seven HVBs (29%) incubating at 33 ∘ C-38 ∘ C. Duration of bioburden reduction step varied from 6 to 48 hours, with a majority of the HVBs incubating for 18-26 hours at cold temperatures (12 of 16 banks = 75%). Those using physiological temperatures (33 ∘ C-38 ∘ C) incubated for either 18-26 hours (3 of 7 banks = 43%) or 6-12 hours (4 of 7 banks = 57%). Two HVBs conducted bioburden reduction at ambient temperature for 24 hours. One HVB decontaminated allografts at either 37 ∘ C for 6-8 hours or 4 ∘ C for 18-24 hours (Table 6) .
92% of HVBs (22 of 24 banks) used controlled rate freezing to cryopreserve cardiovascular tissues, with the remaining two HVBs using manual freezing in liquid nitrogen vapour phase. All HVBs stored processed allografts at ultralow temperatures (<−135 ∘ C) or in liquid nitrogen vapour phase. Storage duration ranged from 2 to 15 years, with the majority of HVBs (16 of 23 banks = 70%) storing released homografts for five years. The procedures used for processing, bioburden reduction, cryopreservation, and storage had been validated by all responding HVBs.
HVBs' Processing Activities and
Outcomes. 23 HVBs participated in this aspect of study. A summary of the heart valve processing activities and outcomes is presented in Tables 7, 8 , and 9. The annual number of donors and allografts processed by the different HVBs varied extensively both between and within jurisdictions. Donor numbers ranged from 4 to over 3700, with 8 to 8500 allografts processed annually. Many HVBs in Europe, North America, Australasia, and South Africa have less than 50 donors annually. In contrast, there are two, very large HVBs in North America, which processe allografts from more than 1000 donors each year (Table 10) .
On average, 70% of the processed allografts (range = 39%-90%; mean = 69%) met the HVBs' release criteria. Twenty-one HVBs (21 of 23 banks = 91%) reported positive microbiology results as a primary reason for allografts failing to meet release criteria. Ten (10 of 23 banks = 43%) listed abnormal morphology of tissues, which is defined as presence of calcification, excessive atheroma (particularly in aortic valves), excessive fenestrations, fibrosis, dilatation, and sinus aneurysm, as a reason for product failure. Positive serology results of donor, valve incompetency during testing, technical issues, quality, and donor related findings (e.g., medical contraindication) were also cited as reasons for product failure. One large North American HVB deferred further processing of donor tissues based on low clinical demand of a certain valve type (i.e., aortic valve) and valve sizes (Table 11) .
On average, 85% of allografts meeting release criteria (range = 50%-100%) were implanted. Uncontrollable factors such as low demand for aortic valves, nonvalve allografts, and certain valve sizes were cited as the primary reason for released products not being implanted by 17 HVBs (17 of 23 banks = 74%). The majority of these valves were discarded due to reaching maximum storage duration. Clinical decision during surgery was also cited as a reason why valves were not implanted. Other factors, which could be monitored and potentially improved upon, include perioperative incidents, such as incorrect valve size delivered to implant hospitals, damage during thawing, and intraoperative contamination of allograft. Four HVBs cited these factors as reasons that prevented implantation of released allografts (4 of 23 banks = 17%) (Table 11 ).
Discussion
Based on the information published in 2004, there are 85 HVBs worldwide, with the majority located in Europe, Canada, USA, and Australia. There are only three HVBs in Asia [5] . From the responses collated from 24 of these HVBs located in various jurisdictions, it is obvious that global harmonisation of heart valve manufacturing procedures has not been achieved. This is not surprising, as each country has different microbial, environmental, regulatory, and logistical challenges to overcome. Despite so, the more routine processing aspects appeared to be relatively standardised. These included (1) the use of sterile culture media for all processing steps, with the majority of banks using either M199 or RPMI-1640, (2) the use of DMSO as a cryoprotectant, with 72% of the banks utilising this reagent at a concentration of 9%-11%, (3) bioburden reduction by antibiotic disinfection, (4) controlled rate freezing for cryopreservation of allografts, and (5) storage of allografts at ultralow temperatures of below −135 ∘ C or in liquid nitrogen vapour phase.
However, in terms of procedural details, numerous differences were also identified. They included (1) type of sterile culture media used for processing, (2) antibiotics combination, (3) temperature and duration used for bioburden reduction, (4) concentration of DMSO used for cryopreservation, and (5) storage duration for released homografts. These differences in processes, which in some cases had been patented by the individual HVBs, had been validated.
Antibiotic cocktails used for bioburden reduction were diverse in terms of the number, combination, and concentrations of antibiotics used. Vancomycin and gentamicin were the most commonly used antibiotics, with approximately 80% of HVBs using one or both of these antibiotics. It is noteworthy that some HVBs were found to prefer first-generation antibiotics, such as penicillin and streptomycin, whereas others chose to use newer, broader spectrum antimicrobials, such as vancomycin and gentamicin. The decision to retain the antibiotics cocktail is probably because the effectiveness of these antibiotics had been validated by the HVBs and no protocol change was warranted. However, as continuous improvement in tissue manufacturing is encouraged, it is important that HVBs routinely review their antibiotic regimens, concentrations, and incubation conditions, to ensure optimal product quality, function, and safety. The incubation temperature used for bioburden reduction also varied. Interestingly, there appeared to be a regional preference for different tissue incubation temperatures. This trend had previously been reported by Parker. In his study, he found that most tissue banks in Europe and North America treated allografts with antibiotics at 4 ∘ C, whereas banks in Australia conducted antibiotics decontamination step at 37 ∘ C [6] . Our survey confirmed these findings, with most banks in Europe and North America incubating recovered donor tissues at 1 ∘ C-10 ∘ C for 18-24 hours and the majority of banks in Australasia incubating at 35 ∘ C-37 ∘ C for 6-12 hours. One Australasian HVB had validated both temperatures (4 ∘ C and 37 ∘ C) for varying durations (18-24 hours and 6-8 hours, resp.) to ensure that processing could be completed within the required time frame. Differences in duration and temperature of bioburden reduction step, as well as the combination and concentration of antibiotics used by individual HVBs, can be attributed to a number of factors. Firstly, the fact that each procedure had been validated, in some cases patented, and shown to be effective in removing detectable microbial contamination from the allografts, justifies the retention of both antibiotic cocktail and incubation procedure for each HVB. In addition, differences in endemic microorganisms sensitive to different antibiotics are also valid reasons for maintaining these procedural differences between different HVBs.
Although different antibiotics function optimally within specific temperature ranges and possess varying degrees of stability, maximal antibiotic activity is generally achieved at a physiological temperature of 37 ∘ C, when most microorganisms are actively replicating [7, 8] . A comprehensive study conducted in 2010 by Germain et al. demonstrated that exposure to antibiotics at 37 ∘ C resulted in a rapid decrease in the number of colony-forming units of 12 bacterial strains [8] . In addition, the results of a recent study by Fan et al. suggested that the lower decontamination success rate observed when bioburden reduction step was conducted at 4 ∘ C was because the micro-organisms were not actively replicating at this temperature. This was particularly relevant for slow-growing organisms, such as the common skin contaminant, Propionibacterium acnes [9] . However, it is recognised that disinfecting tissues at this lower temperature has the advantages of reducing bacterial proliferation, as well as preventing warm ischemia damage to the tissue [9, 10] . To minimise potential ischemic damage, most HVBs that incubated allografts at 37 ∘ C used an incubation time of ≤12 hours [7] .
It is noteworthy that the antifungal drug, amphotericin B, was included in the antibiotic cocktail of some HVBs, when its usage had been discontinued in others [7, 11] . Deleterious effects of amphotericin B on human tissue viability and cell damage were reported by various studies [12, 13] . However, the necessity to preserve cell viability for optimal graft function remained controversial. There is clinical evidence that viable valves at the time of cryopreservation had a lower level of structural deterioration than that of nonviable valves. Such valves were more likely to retain thicker leaflets and fewer perforations, as compared with nonviable valves [14] . Conversely, studies have reported the loss of cell viability after cryopreservation and thawing, suggesting that viable cells might not contribute to valve function and durability in situ [15] . It has even been suggested that the presence of viable cells in the graft may actually increase immunogenicity in Journal of Transplantation situ [16, 17] . Nonetheless, the presence of viable cells precryopreservation is recognised as a useful indicator of optimal tissue preservation [14] . Despite the extensive variation in antibiotic regimens, reported decontamination success rates remain comparable at between 60% and 70% for different HVBs [9] . This confirmed the results of our survey where the mean proportion of allografts meeting clinical release criteria was found to be 69%. However, when comparing the proportion of valves meeting release criteria achieved by individual HVBs, the results were actually quite disparate (range = 39%-90%). This finding appeared to reflect the stage at which tissue exclusion criteria were applied. Some HVBs might have processed all donors' tissues prior to application of tissue exclusion criteria, while others ensured that the criteria were met prior to processing. One large North American HVB chose not to process valves based on low clinical demand for the valve type (i.e., aortic valve) and/or size, which reduced the proportion of their products released for implant to only 39%.
Storage duration for released valves ranged from 2 to 15 years, with the majority of HVBs (∼70%) storing the allografts for 5 years. Some groups advocated that allografts should be stored for ≤5 years. However, this limit was based on convention rather than a validated study. Mirabet et al. concluded that any significant loss of cell viability in tissues stored in liquid nitrogen for ≤13 years was due to freezing and thawing protocols rather than the storage duration [18] .
Almost all HVBs cited "positive microbiological culture of graft" as one of the primary reasons for allografts failing to meet release criteria. Several factors, such as the recovery site environment, sequence of tissue recovery, aseptic recovery and processing techniques, and suboptimal effectiveness of antibiotics used for decontamination, could contribute to this result. Fan et al. reported a significantly higher initial contamination rate of arterial tissues compared to heart tissues, which was ascribed to the less sterile state of the abdominal compartment where the arteries were recovered, especially if trauma was involved [9] . The Prince Charles Hospital also reported high contamination rates when they initiated valve retrieval from multiorgan donors. A review of procedures found contamination to be more common if previous retrieval teams had perforated the bowel or the heart had been removed with instruments used to retrieve other tissues. A higher incidence of contamination has also been reported for valves recovered in an open mortuary area due to the reduced air quality of the mortuary environment [7] . Given the numerous sources for potential contamination, effective aseptic practices at all stages of tissue recovery and processing are essential to minimise the risk of tissue contamination and loss of products.
Over the last thirty years, there has been a significant change in clinical demand for allografts from aortic valves to pulmonary valves. The reasons for this change include an increase in paediatric cardiac surgery, the adoption of the Ross procedure, and improved durability of aortic porcine valves [19, 20] . Various reports also associated the use of aortic valves with more rapid failure than pulmonary valves [21, 22] . The reduced clinical demand for aortic valves, along with low demand for certain valve sizes, were cited as the primary reasons why released valves were not implanted by the majority of HVBs. Together, these valves represented the majority of grafts discarded due to maximum storage duration attained. Other graft types, such as patches, face a similar challenge due to the ready availability of cost-effective animal-sourced patches.
There are several limitations to this study. Firstly, there were only 24 HVBs, which participated in this survey. This means that the processing practices and outcomes of many other HVBs remain unknown. Secondly, although all HVBs performed formal validation on major processes, the test methodologies used were different. Thirdly, there is a lack of patient-related parameters, which are more accurate measurements to the quality of final products and, ultimately, the success of transplanted allografts. Ideally, parameters such as early leaflet failure, iatrogenic infection, and other perioperative adverse events of patients, due to processing variables and thawing protocols, should be reviewed. While beyond the scope of this paper, a separate study should be performed to address these issues and potentially identify practical solutions.
Although the findings of this survey suggested that procedures currently in use by the individual HVBs were validated, in consideration of the wide variation in percentage of allografts fulfilling release requirements (range = 39%-90%), some purportedly validated protocols may not be performing as optimally as others. This seems to present an opportunity for improvement in the heart valve banking industry. As underperforming protocols will incur substantial losses to HVBs, all efforts to improve HVBs' processing activities and recipient outcomes should be encouraged. Although "global harmonisation" is a worthy goal, it is doubtful if this can be achieved in the heart valve banking industry for a number of reasons, which include patented processes, organisational restrictions, and environmental differences. However, regular reviews of important outcomes as cited in this paper and monitoring of adverse patient events should encourage comparison and improvements in the HVBs' processes.
